Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Clinical trial NCT06202066 · SUSPENDED

Trial details

NCT number: NCT06202066
Sponsor: Roswell Park Cancer Institute
Status: SUSPENDED
Phase: Phase 2
Study type: INTERVENTIONAL

Digestive System Neuroendocrine Neoplasm Lung Neuroendocrine Neoplasm Malignant Solid Neoplasm Pancreatic Neuroendocrine Neoplasm

Start date: 2026-10-15
Primary completion: 2027-10-15
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.